Good Life Advisors LLC Acquires 198 Shares of Becton, Dickinson and Company (NYSE:BDX)

Good Life Advisors LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 20.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,145 shares of the medical instruments supplier’s stock after purchasing an additional 198 shares during the period. Good Life Advisors LLC’s holdings in Becton, Dickinson and Company were worth $276,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Wedmont Private Capital purchased a new position in Becton, Dickinson and Company during the first quarter valued at $227,000. Strong Tower Advisory Services lifted its position in shares of Becton, Dickinson and Company by 7.5% in the first quarter. Strong Tower Advisory Services now owns 4,999 shares of the medical instruments supplier’s stock valued at $1,220,000 after acquiring an additional 349 shares in the last quarter. Jacobs & Co. CA lifted its position in shares of Becton, Dickinson and Company by 1.0% in the first quarter. Jacobs & Co. CA now owns 47,939 shares of the medical instruments supplier’s stock valued at $11,862,000 after acquiring an additional 456 shares in the last quarter. Fermata Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 12.0% in the first quarter. Fermata Advisors LLC now owns 1,238 shares of the medical instruments supplier’s stock valued at $306,000 after acquiring an additional 133 shares in the last quarter. Finally, DLK Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 7.8% in the first quarter. DLK Investment Management LLC now owns 18,174 shares of the medical instruments supplier’s stock valued at $4,497,000 after acquiring an additional 1,320 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several research analyst reports. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Trading Up 1.4 %

BDX opened at $243.75 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company’s 50 day simple moving average is $237.01 and its two-hundred day simple moving average is $235.18. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $262.23. The firm has a market capitalization of $70.45 billion, a price-to-earnings ratio of 53.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.96 EPS. Analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were issued a $0.95 dividend. The ex-dividend date was Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.56%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.